In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease

The FDA has recommended additional MRI monitoring during initiation of treatment with the amyloid beta-directed monoclonal antibody lecanemab-irmb (Leqembi)1 and has approved a new subcutaneously injected formulation of the drug (Leqembi Iqlik) for maintenance treatment of Alzheimer's disease.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2025-11-10
DOI: https://doi.org/10.58347/tml.2025.1741d
Primary Topic: Alzheimer's disease research and treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease

Nov 10, 2025

The medical letter on drugs and therapeutics/The medical letter

Alzheimer's disease research and treatments

article

In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease

November 10, 2025article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 67(1741)

Openalex Percentile: Top 59%

Alzheimer's disease research and treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease · The medical letter on drugs and therapeutics/The medical letter (2025) | TGRS Research Map | TGRS